GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XBiotech Inc (STU:4XB) » Definitions » Institutional Ownership

XBiotech (STU:4XB) Institutional Ownership : 6.89% (As of Jun. 20, 2024)


View and export this data going back to 2015. Start your Free Trial

What is XBiotech Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, XBiotech's institutional ownership is 6.89%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, XBiotech's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, XBiotech's Float Percentage Of Total Shares Outstanding is 58.55%.


XBiotech Institutional Ownership Historical Data

The historical data trend for XBiotech's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XBiotech Institutional Ownership Chart

XBiotech Historical Data

The historical data trend for XBiotech can be seen below:

2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31
Institutional Ownership 8.76 8.82 6.82 6.83 6.80 6.81 6.82 6.81 6.69 6.89

XBiotech Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


XBiotech (STU:4XB) Business Description

Traded in Other Exchanges
Address
5217 Winnebago Lane, Austin, TX, USA, 78744
XBiotech Inc is a United States based clinical-stage biopharmaceutical company. It is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-IL-1 a therapeutic antibody as a treatment for cancer. Geographically, all of its operations are in the United States.

XBiotech (STU:4XB) Headlines

No Headlines